Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 18 and 64 years of age, inclusive, at the screening visit with a diagnosis of schizophrenia as defined by DSM-V criteria.~* Body mass index between 18 and 35 kg/m\^2 at the screening visit.~* Good physical health as determined by no clinically significant deviation from normal.~* Ability to provide informed consent and/or consent obtained from a legally acceptable representative (as required by IRB), prior to the initiation of any protocol-required procedures.~* Male and female subjects who are surgically sterile, female subjects who have been postmenopausal for at least 12 consecutive months prior to the screening visit, or male subjects/female subjects (of childbearing potential) who agree to remain abstinent or to practice 2 of the approved birth control methods from the screening visit and for at least 150 days after the dose of IMP for a female subject or 180 days after the dose of IMP for a male subject.~Exclusion Criteria:~* Subjects who have:~* Met DSM-V criteria for substance use disorder within the past 180 days; including alcohol and benzodiazepines, excluding caffeine/nicotine.~* A positive drug screen for drugs of abuse (excluding stimulants, other prescribed medications, and marijuana \[if in investigator's documented opinion the subject does not meet DSM-V criteria for substance use disorder\]).~* Use of more than 1 psychotropic medication at the screening or baseline visit, except for oral brexpiprazole administered during the brexpiprazole tolerability testing (if applicable) and current oral antipsychotic medication.~* Use of varenicline beyond screening.~* Subjects who have participated in any clinical trial involving a psychotropic medication within 1 month prior to the administration of IMP or 5 half-lives from last IMP administration whichever is longer.~* Subjects who have a significant risk of committing suicide based on history, routine psychiatric status examination, investigator's judgment, or who have an answer of yes on questions 4 or 5 on the Baseline Version of the C-SSRS.~* Subjects currently in an acute relapse of schizophrenia as assessed by the investigator.~* Subjects with a current DSM-V diagnosis other than schizophrenia. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Single Dose Injection: Subcutaneous (Type: EXPERIMENTAL): Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
- Part A: Single Dose Injection: Intramuscular (Type: EXPERIMENTAL): Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
- Part B: Cohort 1 (Type: EXPERIMENTAL): Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
- Part B: Cohort 2 (Type: EXPERIMENTAL): Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
- Part B: Cohort 3 (Type: EXPERIMENTAL): Drug: Brexpiprazole, OPDC-34712 Once, SC or IM

Based on this trial design, predict the completion outcome and termination type (if applicable).